Exclusive Summary

• Addresses a critical, unmet medical need in a completely blank market: With zero approved treatments globally for Bronchopulmonary Dysplasia (BPD), UB704 targets a life-threatening disease in extreme premature infants natively.
• Best-in-Class potential via long-acting differentiation: Utilizing protein/fatty acid chain conjugation, UB704 overcomes the continuous intravenous (IV) infusion burden of competitors (e.g., OHB-607), enabling convenient weekly subcutaneous (SC) dosing while reducing hypoglycemia risks.
• Superior preclinical efficacy and safety profiles: Demonstrated significantly more stable PK exposure compared to short-acting IGF-1 and superior improvement in alveolar structures in animal models compared to the clinical-stage competitor OHB-607.
• High regulatory and commercial out-licensing value: Targeting rare pediatric diseases strongly positions UB704 for lucrative regulatory incentives in Western markets, including Orphan Drug Designation (ODD) and the highly monetizable Rare Pediatric Disease Priority Review Voucher (PRV).

Asset Materials

Contact Us for Full Materials